Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 13/20 | 1.00 |
| ▸ | CTSK | P43235 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CTSH | P09668 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | CTSL | P07711 | 6/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885834 | 0.92 | CTSC (1.00) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL2885839 | 0.92 | CTSC (1.00) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL8327832 | 0.90 | CTSC (1.00) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL5689164 | 0.88 | CTSC (0.77) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL5464894 | 0.86 | CTSC (1.00) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL5459993 | 0.86 | CTSC (1.00) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL5564477 | 0.79 | CTSC (0.70) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL5564472 | 0.79 | CTSC (0.70) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL29809215 | 0.79 | CTSC (0.65) | CTSCCTSKCYP1A2CYP3A4CTSH | |
| SCHEMBL9225086 | 0.79 | CTSC (0.66) | CTSCCTSKCYP1A2CYP3A4CTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | claimed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | disclosed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | disclosed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | disclosed |
| EP-1638925-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099958-A1 | Protease inhibitors | CTSC, DPP7, BACE1 | CTSC 1/4885CTSK 5/4885CYP1A2 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.